502133-62-2 Usage
Class
Secondary alkylamines
It belongs to a group of organic compounds that contain a nitrogen atom bonded to two carbon atoms.
Structure
Five-membered azepane ring
The compound has a ring structure consisting of five atoms, including nitrogen.
Substituents
Chloropyridine at the 1-position and dimethylamine at the 4-position
The chloropyridine group is attached to the first carbon atom of the azepane ring, while the dimethylamine group is attached to the fourth carbon atom.
Applications
Pharmaceutical and drug synthesis
The compound is used in the development and synthesis of various pharmaceuticals and drugs.
Biological activities
Potential therapeutic applications
It may exhibit various biological activities and is being researched for its potential use in treating medical conditions.
Safety
Proper handling and safety protocols required
Due to its potential hazards, it is important to handle 1-(5-chloropyridin-2-yl)-1,4-diazepane with care and follow appropriate safety measures.
Check Digit Verification of cas no
The CAS Registry Mumber 502133-62-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,2,1,3 and 3 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 502133-62:
(8*5)+(7*0)+(6*2)+(5*1)+(4*3)+(3*3)+(2*6)+(1*2)=92
92 % 10 = 2
So 502133-62-2 is a valid CAS Registry Number.
502133-62-2Relevant academic research and scientific papers
Al-Ghanim, Lamya,Zhu, Xue Y.,Asong, Gladys,Ablordeppey, Seth Y.
, p. 2421 - 2426 (2019)
Several lines of evidence suggest that selective sigma-2 (σ2) ligands might be useful for the treatment of solid tumors. However, very few selective σ2 ligands have been identified. This study was aimed at identifying new selective σ
INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE
-
, (2019/08/20)
Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic disorders, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.
